Literature DB >> 10415161

Regulation of macrophage migration inhibitory factor (MIF) expression by glucose and insulin in adipocytes in vitro.

S Sakaue1, J Nishihira, J Hirokawa, H Yoshimura, T Honda, K Aoki, S Tagami, Y Kawakami.   

Abstract

BACKGROUND: It has been reported that macrophage migration inhibitory factor (MIF) stimulated insulin secretion from pancreatic islet beta-cells in an autocrine manner, which suggests its pivotal role in the glucose metabolism. According to this finding, we evaluated MIF expression in cultured adipocytes and epididymal fat pads of obese and diabetic rats to investigate its role in adipose tissue.
MATERIALS AND METHODS: The murine adipocyte cell line 3T3-L1 was used to examine MIF mRNA expression and production of MIF protein in response to various concentrations of glucose and insulin. Epididymal fat pads of Otsuka Long-Evans Tokushima fatty (OLETF) and Wistar fatty rats, animal models of obesity and diabetes, were subjected to Northern blot analysis to determine MIF mRNA levels.
RESULTS: MIF mRNA of 3T3-L1 adipocytes was up-regulated by costimulation with glucose and insulin. Intracellular MIF content was significantly increased by stimulation, whereas its content in the culture medium was decreased. When the cells were treated with cytochalasin B, MIF secretion in the medium was increased. Pioglitazone significantly increased MIF content in the culture medium of 3T3-L1 cells. However, MIF mRNA expression of both epididymal fat pads of OLETF and Wistar fatty rats was down-regulated despite a high plasma glucose level. The plasma MIF level of Wistar fatty rats was significantly increased by treatment with pioglitazone.
CONCLUSION: We show here that the intracellular glucose level is critical to determining the MIF mRNA level as well as its protein content in adipose tissue. MIF is known to play an important role in glucose metabolism as a positive regulator of insulin secretion. In this context, it is conceivable that MIF may affect the pathophysiology of obesity and diabetes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10415161      PMCID: PMC2230432     

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  34 in total

1.  The structure and physicochemical properties of rat liver macrophage migration inhibitory factor.

Authors:  J Nishihira; T Kuriyama; M Sakai; S Nishi; S Ohki; K Hikichi
Journal:  Biochim Biophys Acta       Date:  1995-02-22

2.  Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.

Authors:  S Hallakou; L Doaré; F Foufelle; M Kergoat; M Guerre-Millo; M F Berthault; I Dugail; J Morin; J Auwerx; P Ferré
Journal:  Diabetes       Date:  1997-09       Impact factor: 9.461

3.  Tumor necrosis factor alpha inhibits signaling from the insulin receptor.

Authors:  G S Hotamisligil; D L Murray; L N Choy; B M Spiegelman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

4.  Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells.

Authors:  D Szalkowski; S White-Carrington; J Berger; B Zhang
Journal:  Endocrinology       Date:  1995-04       Impact factor: 4.736

5.  Positional cloning of the mouse obese gene and its human homologue.

Authors:  Y Zhang; R Proenca; M Maffei; M Barone; L Leopold; J M Friedman
Journal:  Nature       Date:  1994-12-01       Impact factor: 49.962

6.  Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance.

Authors:  G S Hotamisligil; P Arner; J F Caro; R L Atkinson; B M Spiegelman
Journal:  J Clin Invest       Date:  1995-05       Impact factor: 14.808

7.  Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance.

Authors:  G S Hotamisligil; N S Shargill; B M Spiegelman
Journal:  Science       Date:  1993-01-01       Impact factor: 47.728

8.  Glutathione binding rat liver 13k protein is the homologue of the macrophage migration inhibitory factor.

Authors:  M Sakai; J Nishihira; Y Hibiya; Y Koyama; S Nishi
Journal:  Biochem Mol Biol Int       Date:  1994-06

9.  Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha.

Authors:  G S Hotamisligil; A Budavari; D Murray; B M Spiegelman
Journal:  J Clin Invest       Date:  1994-10       Impact factor: 14.808

10.  The macrophage is an important and previously unrecognized source of macrophage migration inhibitory factor.

Authors:  T Calandra; J Bernhagen; R A Mitchell; R Bucala
Journal:  J Exp Med       Date:  1994-06-01       Impact factor: 14.307

View more
  14 in total

1.  Oxygen regulation of macrophage migration inhibitory factor in human placenta.

Authors:  Francesca Ietta; Yuanhong Wu; Roberta Romagnoli; Nima Soleymanlou; Barbara Orsini; Stacy Zamudio; Luana Paulesu; Isabella Caniggia
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-08-29       Impact factor: 4.310

Review 2.  The macrophage migration inhibitory factor protein superfamily in obesity and wound repair.

Authors:  Bong-Sung Kim; Norbert Pallua; Jürgen Bernhagen; Richard Bucala
Journal:  Exp Mol Med       Date:  2015-05-01       Impact factor: 8.718

3.  Macrophage migration inhibitory factor deficiency ameliorates high-fat diet induced insulin resistance in mice with reduced adipose inflammation and hepatic steatosis.

Authors:  Orla M Finucane; Clare M Reynolds; Fiona C McGillicuddy; Karen A Harford; Martine Morrison; John Baugh; Helen M Roche
Journal:  PLoS One       Date:  2014-11-20       Impact factor: 3.240

4.  Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites.

Authors:  Peter D Senter; Yousef Al-Abed; Christine N Metz; Fabio Benigni; Robert A Mitchell; J Chesney; Jianlin Han; Carlos G Gartner; Sidney D Nelson; George J Todaro; Richard Bucala
Journal:  Proc Natl Acad Sci U S A       Date:  2002-01-02       Impact factor: 11.205

5.  Effect of macrophage migration inhibitory factor (MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: results from the MONICA/KORA Augsburg Case-Cohort Study, 1984-2002.

Authors:  C Herder; N Klopp; J Baumert; M Müller; N Khuseyinova; C Meisinger; S Martin; T Illig; W Koenig; B Thorand
Journal:  Diabetologia       Date:  2007-08-22       Impact factor: 10.122

Review 6.  The role of macrophage migration inhibitory factor on glucose metabolism and diabetes.

Authors:  C Toso; J A Emamaullee; S Merani; A M J Shapiro
Journal:  Diabetologia       Date:  2008-07-09       Impact factor: 10.122

Review 7.  Clinical potential of insulin therapy in critically ill patients.

Authors:  Dieter Mesotten; Greet Van den Berghe
Journal:  Drugs       Date:  2003       Impact factor: 9.546

8.  Current and emerging strategies for the treatment and management of systemic lupus erythematosus based on molecular signatures of acute and chronic inflammation.

Authors:  Undurti N Das
Journal:  J Inflamm Res       Date:  2010-12-02

9.  Computational promoter analysis of mouse, rat and human antimicrobial peptide-coding genes.

Authors:  Manisha Brahmachary; Christian Schönbach; Liang Yang; Enli Huang; Sin Lam Tan; Rajesh Chowdhary; S P T Krishnan; Chin-Yo Lin; David A Hume; Chikatoshi Kai; Jun Kawai; Piero Carninci; Yoshihide Hayashizaki; Vladimir B Bajic
Journal:  BMC Bioinformatics       Date:  2006-12-18       Impact factor: 3.169

Review 10.  Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities.

Authors:  Robert Kleemann; Richard Bucala
Journal:  Mediators Inflamm       Date:  2010-02-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.